Alectinib Hydrochloride Capsules.

Efficacy and efficacy:
This product is suitable for the treatment of patients with locally advanced or metastatic non-small cell lung cancer who are positive for anaplastic lymphoma kinase (ALK).
Usage and dosage:
This product should be used in medical institutions with experience in use and under the guidance of specific professional technicians. Before taking this product, an ALK positive evaluation result confirmed by a fully validated test method must be obtained. The recommended dose of this product is 600 mg (4 150 mg capsules), twice a day (total daily dose of 1200 mg), oral administration, should be taken with meals, swallowed whole, and cannot be opened or dissolved before taking. Patients are advised to receive this product until the disease progresses or intolerable toxicity occurs. The same drugs produced by different manufacturers may have inconsistent instructions. If you find inconsistent instructions before taking the drug, please consult a doctor or pharmacist in time.
Drug contraindications:
Allergic to this product is prohibited and should be used with caution during pregnancy
Related dosage forms:
Capsules